"""
Question: 1101

Evidence: The genotyping analysis of the samples collected in 2015–2016 was performed in subsequent years (2017–2019) and its completion was delayed due to financial and technical reasons. In this article, the results of the final analysis of all the sequences obtained in this HIVDR study are presented.

Rationale: The paper explicitly states that the analysis of samples collected from 2015-2016 was completed in 2017-2019 and that this article presents the final results of that study. This indicates the data being reported are from a specific study period and had not been published prior to this article.

Answer: Yes
"""

"""
Question: 1102

Evidence: In total, 309 nucleotide sequence consensuses with a length of 911–1,238 bp had been obtained for mutation and subtype analysis in both cohorts. The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The paper directly states that nucleotide sequences were obtained and provides the specific GenBank accession numbers where these HIV sequences are deposited.

Answer: Yes
"""

"""
Question: 1103

Evidence: The paper describes a cross-sectional surveillance study of patient samples and does not mention any in vitro passage experiments. The methods involve sample collection, RNA extraction, amplification, and sequencing from patient plasma.

Rationale: A thorough review of the paper's abstract, introduction, methods, and results sections finds no mention of in vitro passage experiments. The study is observational, based on clinical samples from patients.

Answer: No
"""

"""
Question: 1104

Evidence: The paper focuses on genotypic resistance analysis. The methods describe sequencing and analysis using the Stanford database for drug resistance mutations. The results report the prevalence of mutations and levels of resistance based on penalty scores, not actual in vitro susceptibility tests.

Rationale: The paper exclusively reports genotypic resistance data (mutations and their interpretation via penalty scores). There is no description of phenotypic assays, such as measuring viral growth inhibition in the presence of drugs, which would be required to report in vitro susceptibility data.

Answer: No
"""

"""
Question: 2101

Evidence: The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The paper provides a list of GenBank accession numbers for the HIV sequences generated in this study.

Answer: Yes
"""

"""
Question: 2102

Evidence: The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The paper provides GenBank accession numbers for sequences obtained from clinical HIV isolates from patients in Uzbekistan. There is no mention of sequences from laboratory HIV isolates (e.g., reference strains like HXB2).

Answer: Yes
"""

"""
Question: 2103

Evidence: The obtained nucleotide sequences were deposited in GenBank and are available under accession numbers: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.

Rationale: The paper explicitly lists the GenBank accession numbers for the deposited sequences in the "Sequence data/accession number(s)" section.

Answer: MF401457–MF401512, MF431622–MF431713, MF431717, MF431719, MF497081, MF497088, MF497090–MF497219, MF497220, MF497222–MF497262, and MF497263.
"""

"""
Question: 2202

Evidence: The paper reports aggregate mutation prevalence data (e.g., "M184V/I (49.1%; 52/106)"). Analysis of HIV-1 polregion viral sequences were obtained from 309 patients. The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs).

Rationale: While the paper provides detailed prevalence rates for specific mutations across the cohort, it does not provide lists of mutations linked to individual patient sequences or isolate identifiers.

Answer: No
"""

"""
Question: 2301

Evidence: The paper's title is "Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan". Analysis of HIV-1 genome polregion viral sequences were obtained from 309 patients.

Rationale: The paper exclusively studies HIV-1, as stated in the title and throughout the text. There is no mention of HIV-2 or other HIV species.

Answer: HIV-1
"""

"""
Question: 2302

Evidence: According to the REGA interpretation, most of the viruses were recognized as circulating recombinant form CRF02_AG (176/309, 57.0%). There were four additional subtypes identified: 125 (40.5%) viruses belonged to subtype A1, 3---to subtype B, 2 were defined as recombinant of A1, G, and one to subtype C. Two sequences were preliminarily considered unique recombinant forms (URFs) between subtype A1 and CRF02_AG.

Rationale: The "Results" section under "Distribution of HIV-1 subtypes" provides a detailed breakdown of the subtypes identified among the sequenced viruses.

Answer: CRF02_AG, A1, B, recombinant of A1 and G, C, and unique recombinant forms (URFs) between A1 and CRF02_AG.
"""

"""
Question: 2303

Evidence: HIV-1 genome polregion viral sequences were obtained from 309 patients. Sequencing of obtained HIV genome pol region-amplified products was further performed.

Rationale: The methods and results sections consistently specify that the pol region of the HIV genome was sequenced.

Answer: pol
"""

"""
Question: 2304

Evidence: HIV-1 genome polregion viral sequences were obtained from 309 patients. Analysis of HIV-1 subtypes and drug resistance mutations (DRMs) to HIV protease and reverse transcriptase inhibitors was performed.

Rationale: The paper explicitly states that HIV pol sequences were obtained and analyzed for drug resistance mutations.

Answer: Yes
"""

"""
Question: 2401

Evidence: The paper's title is "Prevalence of Antiretroviral Drug Resistance Mutations Among Pretreatment and Antiretroviral Therapy-Failure HIV Patients in Uzbekistan". A nation-wide, cross-sectional active HIV-1 PDR surveillance was conducted in Uzbekistan from 2015 to 2016.

Rationale: The title and abstract clearly state that the study was conducted in Uzbekistan.

Answer: Uzbekistan
"""

"""
Question: 2402

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016.

Rationale: The "Materials and Methods" section under "Sample size and study participants" specifies the time period during which the samples were collected.

Answer: 2015 to 2016
"""

"""
Question: 2502

Evidence: Sequencing of obtained HIV genome pol region-amplified products was further performed with the Applied Biosystems 3500xL Genetic Analyzer using six primers.

Rationale: The use of the Applied Biosystems 3500xL Genetic Analyzer and Sanger sequencing methodology with a set of primers is described in the "Genotype analysis" section.

Answer: Yes
"""

"""
Question: 2503

Evidence: The paper describes sequencing using an Applied Biosystems 3500xL Genetic Analyzer and six primers, which is characteristic of Sanger sequencing. There is no mention of terms associated with NGS (e.g., next-generation sequencing, deep sequencing, Illumina, MiSeq, Ion Torrent).

Rationale: The methodology described is consistent with Sanger sequencing, and no NGS technologies are referenced.

Answer: No
"""

"""
Question: 2504

Evidence: The methods describe viral RNA extraction, amplification, and direct sequencing of the amplified products. There is no mention of a cloning step prior to sequencing.

Rationale: The "Genotype analysis" section outlines a standard protocol for population-based Sanger sequencing without cloning.

Answer: No
"""

"""
Question: 2505

Evidence: The paper describes standard bulk PCR amplification and sequencing of the pol region. There is no mention of single genome sequencing or single genome amplification (SGA).

Rationale: The methodology section does not describe the use of single genome sequencing.

Answer: No
"""

"""
Question: 2506

Evidence: The methods describe viral RNA extraction, amplification, and sequencing. There is no mention of molecular cloning into a vector.

Rationale: The "Genotype analysis" section does not include any steps involving molecular cloning.

Answer: No
"""

"""
Question: 2601

Evidence: Plasma specimens from 713 HIV-infected patients were collected. The extraction of viral RNA and further amplification were performed.

Rationale: The study collected plasma specimens and performed viral RNA extraction, which is the standard source for plasma virus sequencing.

Answer: Yes
"""

"""
Question: 2602

Evidence: The paper states that "Plasma specimens from 713 HIV-infected patients were collected" and that "viral RNA" was extracted. There is no mention of PBMC isolation, DNA extraction, or proviral DNA sequencing.

Rationale: The methods specifically mention plasma and viral RNA, indicating sequencing of plasma virus. Sequencing from PBMCs or proviral DNA is not described.

Answer: No
"""

"""
Question: 2603

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016.

Rationale: The "Materials and Methods" section states that plasma specimens were collected from 713 patients, indicating that plasma virus sequencing was attempted on all these samples.

Answer: 713
"""

"""
Question: 2604

Evidence: The paper describes the collection of plasma specimens and extraction of viral RNA. There is no mention of PBMC isolation or sequencing from PBMCs.

Rationale: The source material for sequencing is explicitly stated as plasma, not PBMCs.

Answer: 0
"""

"""
Question: 2605

Evidence: The enrollment criteria for the cohort I (PDR) included that the patients provide informed consent, ≥18 years, and with viral load ≥1,000 copies/mL. Recruitment of patients with ART failure (cohort II) was carried out with the criteria: ≥18 years, viral load ≥1,000 copies/mL at the time of enrollment (considered ART failure).

Rationale: A key inclusion criterion for both cohorts was a viral load of ≥1,000 copies/mL, indicating active HIV replication at the time of sampling.

Answer: Yes
"""

"""
Question: 2606

Evidence: The paper describes sequencing from plasma viral RNA. There is no mention of DNA extraction, PBMCs, or sequencing from the proviral DNA reservoir.

Rationale: The methodology is based on plasma viral RNA, not proviral DNA from cells.

Answer: No
"""

"""
Question: 2701

Evidence: The enrollment criteria for the cohort I (PDR) included that the patients provide informed consent, ≥18 years. Recruitment of patients with ART failure (cohort II) was carried out with the criteria: ≥18 years.

Rationale: The inclusion criteria for both study cohorts specify that participants were adults (≥18 years old). There is no mention of infants or children.

Answer: No
"""

"""
Question: 2702

Evidence: The paper describes a nation-wide, cross-sectional surveillance study. There is no description of a clinical trial, intervention, or randomization.

Rationale: The study design is observational surveillance, not a clinical trial.

Answer: No
"""

"""
Question: 2703

Evidence: The paper describes a surveillance study of patients in the national ART program. There is no mention of a clinical trial.

Rationale: The study is an observational cross-sectional survey, not a clinical trial.

Answer: No
"""

"""
Question: 3101

Evidence: Plasma specimens from 713 HIV-infected patients were collected between May 2015 and January 2016.

Rationale: The "Materials and Methods" section states that plasma specimens were collected from 713 patients, indicating that samples were obtained from this number of individuals for the purpose of HIV sequencing.

Answer: 713
"""

"""
Question: 3102

Evidence: In total, 309 nucleotide sequence consensuses with a length of 911–1,238 bp had been obtained for mutation and subtype analysis in both cohorts; among them, 203 in PDR cohort I and 106 in ADR cohort II.

Rationale: While samples were obtained from 713 individuals, successful sequencing was only achieved for 309 of them, as stated in the results.

Answer: No
"""

"""
Question: 4101

Evidence: In total, 713 blood plasma samples from adults were collected, including samples from ART-naive patients initiating ART and ART-failure HIV patients. Of totally enrolled 713 patients, there were 344 HIV-positive adults enrolled into the PDR study (cohort I).

Rationale: The abstract and results sections confirm that one cohort (cohort I, PDR) consisted of ART-naive patients.

Answer: Yes
"""

"""
Question: 4102

Evidence: In total, 713 blood plasma samples from adults were collected, including samples from ART-naive patients initiating ART and ART-failure HIV patients. Of totally enrolled 713 patients, there were 344 HIV-positive adults enrolled into the PDR study (cohort I) and 369 into the ADR study (cohort II).

Rationale: The abstract and results sections confirm that one cohort (cohort II, ADR) consisted of ART-experienced patients (those with ART failure).

Answer: Yes
"""

"""
Question: 4103

Evidence: In total, 713 blood plasma samples from adults were collected, including samples from ART-naive patients initiating ART and ART-failure HIV patients. Of totally enrolled 713 patients, there were 344 HIV-positive adults enrolled into the PDR study (cohort I) and 369 into the ADR study (cohort II).

Rationale: The paper explicitly states that sequences were obtained from both ART-naive (cohort I) and ART-experienced (cohort II) individuals.

Answer: Yes
"""

"""
Question: 4104

Evidence: Of totally enrolled 713 patients, there were 344 HIV-positive adults enrolled into the PDR study (cohort I).

Rationale: The "Results" section under "Study population" specifies that 344 patients were enrolled in the ART-naive PDR cohort.

Answer: 344
"""

"""
Question: 4105

Evidence: A simple questionnaire with essential data, including antiretroviral therapy history for the ART failure - aquired drug resistance (ADR) cohort, was applied to each case before blood specimen withdrawal. The paper provides a table (Table 2) showing the distribution of therapy regimens in the ADR cohort.

Rationale: While therapy history is provided for the ART-failure cohort in aggregate (Table 2), the paper does not state that complete individual-level ART history was available for all participants, especially for the large PDR cohort where prior exposure was assessed but not found.

Answer: No
"""

"""
Question: 4201

Evidence: ART-naive cohort I (PDR) included six samples that contained at least one surveillance drug resistance mutation (SDRM) (2.96%), with the most common being K103N mutation (4/6).

Rationale: The paper reports the prevalence of drug resistance mutations in ART-naive individuals, which defines transmitted HIV drug resistance.

Answer: Yes
"""

"""
Question: 4202

Evidence: ART-naive cohort I (PDR) included six samples that contained at least one surveillance drug resistance mutation (SDRM) (2.96%), with the most common being K103N mutation (4/6).

Rationale: The paper explicitly reports the prevalence of pretreatment drug resistance (PDR) in the ART-naive cohort.

Answer: Yes
"""

"""
Question: 4301

Evidence: According to the data from Republican AIDS Center MoHUz, at the beginning of the blood sample collection in 2015, the main therapy regimens used as first-line therapy in Uzbekistan were as follows: tenofovir (TDF)/zidovudine (AZT)/abacavir (ABC)+emtricitabine (FTC)/lamivudine (3TC) as the NRTI backbone; efavirenz (EFV)/nevirapine (NVP) as the third NNRTI drug were administered to 100% of the patients. The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used.

Rationale: The "Introduction" section details the drug classes (NRTIs, NNRTIs, PIs, INSTIs) used in the national ART program during the study period.

Answer: NRTIs, NNRTIs, PIs, INSTIs
"""

"""
Question: 4302

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used.

Rationale: The paper mentions that a small percentage (4.0%) of patients received INSTIs (RAL or DTG).

Answer: Yes
"""

"""
Question: 4303

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used.

Rationale: The paper explicitly states that PI-based regimens were used as second-line therapy.

Answer: Yes
"""

"""
Question: 4304

Evidence: Table 2 shows the distribution of various therapy regimens in the ADR cohort, including multiple combinations of NRTIs and NNRTIs, and some PI-based regimens.

Rationale: Table 2 lists multiple different ART regimens received by the patients in the ART-failure cohort, demonstrating that not all individuals received the same therapy.

Answer: No
"""

"""
Question: 4305

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used.

Rationale: The text states that only 4.0% of patients received INSTIs, implying that the vast majority (96%) were INSTI-naive. However, it does not explicitly state that all individuals were INSTI-naive, as a small fraction received them.

Answer: No"""
Question: 4403

Evidence: The paper provides a table (Table 2) showing the distribution of various first-line and second-line regimens in the ADR cohort. Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens.

Rationale: The paper distinguishes between patients failing first-line regimens and those failing second-line regimens. The number of patients who received more than one regimen (i.e., second-line) is explicitly stated as 54.

Answer: 54
"""

"""
Question: 4404

Evidence: The paper only distinguishes between first-line and second-line therapy regimens. There is no mention of patients receiving more than two ART regimens.

Rationale: The therapy history described in the paper is limited to first-line and second-line regimens. No information is provided about third-line regimens or patients receiving more than two distinct ART regimens.

Answer: NA
"""

"""
Question: 4405

Evidence: Table 2 shows the distribution of various therapy regimens in the ADR cohort, including both first-line and second-line regimens. Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens... The rest of the patients failed on first-line ART regimens.

Rationale: The data clearly show that patients received different numbers of ART regimens - some failed on first-line, others on second-line therapy.

Answer: No
"""

"""
Question: 4406

Evidence: Among adults from cohort II with ART failure, only 54 (14.7%) received the second-line treatment regimens that included 2NRTI+LPV/rtv. The rest of the patients failed on first-line ART regimens.

Rationale: Since 54 patients received second-line therapy, they necessarily received more than one ART regimen. Therefore, not all individuals received only one ART regimen.

Answer: No
"""

"""
Question: 4501

Evidence: The PI-based ART regimens were used as second-line only and were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%); in 4.0% of the patients, INSTI (RAL or DTG) drugs were used.

Rationale: While the paper mentions that INSTIs (including DTG) were used in 4.0% of patients, it does not provide the exact number of individuals who received dolutegravir specifically, nor does it break down the 4.0% between RAL and DTG.

Answer: NA
"""

"""
Question: 4502

Evidence: The paper mentions that PI-based regimens were mostly limited to ritonavir-boosted lopinavir (LPV/rtv; 96.0%). There is no mention of darunavir being used in the study population.

Rationale: The only protease inhibitor specifically named in the context of the regimens used is lopinavir. Darunavir is not mentioned anywhere in the paper.

Answer: 0
"""

"""
Question: 5101

Evidence: ART-naive cohort I (PDR) included six samples that contained at least one surveillance drug resistance mutation (SDRM) (2.96%). In ART-experienced patients, cohort II, 77.4% (82/106) of viruses contained at least one mutation against PIs, NRTIs, or NNRTIs.

Rationale: The paper provides separate counts for ART-naive individuals with DRMs (6) and ART-experienced individuals with DRMs (82). However, it does not provide a combined total for all individuals in the paper.

Answer: For ART-naive: 6; For ART-experienced: 82
"""

"""
Question: 5102

Evidence: The paper reports mutations against PIs, NRTIs, and NNRTIs. There is no mention of INSTI-resistance mutations being found or analyzed.

Rationale: The results sections on drug resistance mutations only discuss mutations related to protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors. INSTI resistance is not reported.

Answer: 0
"""

"""
Question: 5103

Evidence: The most common NRTI resistance mutations were M184V/I (49.1%; 52/106), A62V (36.8%; 39/106), and K65R (18.9%; 20/106) mutations. The paper does not specifically report TDF-resistance mutations or provide a count of individuals with TDF resistance.

Rationale: While mutations like K65R are associated with TDF resistance, the paper does not explicitly state how many individuals had TDF-resistance mutations or provide a specific analysis for TDF resistance.

Answer: NA
"""

"""
Question: 5104

Evidence: The paper reports mutations against PIs, NRTIs, and NNRTIs. There is no mention of INSTI-resistance mutations being found or analyzed.

Rationale: The results sections on drug resistance mutations only discuss mutations related to protease inhibitors, nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors. No INSTI-resistance mutations are reported.

Answer: None reported
"""

"""
Question: 6101

Evidence: The paper focuses on genotypic resistance analysis using sequencing and the Stanford database. HIV-1 pol genome region sequencing was performed. The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs).

Rationale: The methodology describes genotypic testing (sequencing) but does not mention any phenotypic susceptibility tests being performed.

Answer: No phenotypic susceptibility test was used
"""

"""
Question: 6102

Evidence: The paper reports genotypic resistance data based on mutation analysis and Stanford penalty scores. There is no mention of IC50, IC90, or any other inhibitory concentration values.

Rationale: The results are presented as prevalence of mutations and levels of resistance based on genotypic penalty scores, not as IC values from phenotypic assays.

Answer: No
"""

"""
Question: 6103

Evidence: The paper reports genotypic resistance data based on mutation analysis and Stanford penalty scores. There is no mention of IC50 fold change values or any other phenotypic susceptibility measurements.

Rationale: The methodology and results are exclusively genotypic, with no phenotypic data reported.

Answer: No
"""

"""
Question: 6104

Evidence: The paper describes genotypic sequencing methods but does not describe any phenotypic susceptibility assays being used. HIV-1 pol genome region sequencing was performed. The HIVdb program tool of the Stanford database was used to assess HIV drug resistance mutations (DRMs).

Rationale: No phenotypic susceptibility assay is mentioned in the methods or results sections.

Answer: No phenotypic susceptibility assay was used
"""

"""
Question: 6105

Evidence: The paper reports on drug resistance mutations and their prevalence. There is no mention of replication capacity assays or data.

Rationale: The study focuses on resistance mutation prevalence and does not include any assessment of viral replication capacity.

Answer: No
"""

"""
Question: 6106

Evidence: The paper does not describe any phenotypic susceptibility testing being performed on the HIV isolates.

Rationale: Since no phenotypic susceptibility testing was conducted, no drugs were tested using such assays.

Answer: No drugs were tested using phenotypic susceptibility assays
"""

"""
Question: 7101

Evidence: The paper describes sequencing of HIV from clinical patient samples. There is no mention of site-directed mutagenesis or engineered viral isolates.

Rationale: All sequences were obtained directly from patient plasma samples as part of a surveillance study. The methodology does not involve creating site-directed mutants.

Answer: No
"""

"""
Question: 7102

Evidence: The paper describes a cross-sectional surveillance study of clinical samples. There is no mention of in vitro passage experiments or viruses resulting from such experiments.

Rationale: The study design involves direct analysis of patient-derived viruses without any in vitro passage or selection experiments.

Answer: No
"""